During the last session, Vera Therapeutics Inc (NASDAQ:VERA)’s traded shares were 2.94 million, with the beta value of the company hitting 0.99. At the end of the trading day, the stock’s price was $40.64, reflecting an intraday loss of -5.42% or -$2.33. The 52-week high for the VERA share is $50.78, that puts it down -24.95 from that peak though still a striking 76.18% gain since the share price plummeted to a 52-week low of $9.68. The company’s market capitalization is $2.23B, and the average intraday trading volume over the past 10 days was 1.1 million shares, and the average trade volume was 581.98K shares over the past three months.
Vera Therapeutics Inc (VERA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.20. VERA has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.66.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Vera Therapeutics Inc (NASDAQ:VERA) trade information
Vera Therapeutics Inc (VERA) registered a -5.42% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -5.42% in intraday trading to $40.64, hitting a weekly high. The stock’s 5-day price performance is 1.88%, and it has moved by -5.11% in 30 days. Based on these gigs, the overall price performance for the year is 275.95%. The short interest in Vera Therapeutics Inc (NASDAQ:VERA) is 6.19 million shares and it means that shorts have 8.96 day(s) to cover.
The consensus price target of analysts on Wall Street is $34, which implies a decrease of -19.53% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $38 respectively. As a result, VERA is trading at a premium of 6.5% off the target high and 85.24% off the low.
Vera Therapeutics Inc (VERA) estimates and forecasts
Statistics show that Vera Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Vera Therapeutics Inc (VERA) shares have gone down -3.97% during the last six months, with a year-to-date growth rate less than the industry average at -14.22% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -46.70% this quarter and then drop -16.70% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 10.22%. While earnings are projected to return -12.27% in 2024.
VERA Dividends
Vera Therapeutics Inc is due to release its next quarterly earnings in November. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Vera Therapeutics Inc (NASDAQ:VERA)’s Major holders
Vera Therapeutics Inc insiders own 7.82% of total outstanding shares while institutional holders control 109.88%, with the float percentage being 119.20%. AVORO CAPITAL ADVISORS LLC is the largest shareholder of the company, while 254.0 institutions own stock in it. As of 2024-06-30, the company held over 4.31 million shares (or 8.4548% of all shares), a total value of $155.92 million in shares.
The next largest institutional holding, with 3.62 million shares, is of PRICE T ROWE ASSOCIATES INC /MD/’s that is approximately 7.1022% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $130.98 million.
